303 related articles for article (PubMed ID: 21708402)
21. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
[TBL] [Abstract][Full Text] [Related]
22. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
23. Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.
Shan L; Chen YA; Davis L; Han G; Zhu W; Molina AD; Arango H; LaPolla JP; Hoffman MS; Sellers T; Kirby T; Nicosia SV; Sutphen R
PLoS One; 2012; 7(10):e46846. PubMed ID: 23082132
[TBL] [Abstract][Full Text] [Related]
24. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
25. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.
Pearl ML; Zhao Q; Yang J; Dong H; Tulley S; Zhang Q; Golightly M; Zucker S; Chen WT
Gynecol Oncol; 2014 Sep; 134(3):581-90. PubMed ID: 24972191
[TBL] [Abstract][Full Text] [Related]
26. Validation of serum biomarkers for detection of early-stage ovarian cancer.
Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
[TBL] [Abstract][Full Text] [Related]
27. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.
Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I
Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897
[TBL] [Abstract][Full Text] [Related]
28. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
Chan KK; Chen CA; Nam JH; Ochiai K; Wilailak S; Choon AT; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Sumpaico WW
Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
Fan HY; Duan DM; Liu YF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
[TBL] [Abstract][Full Text] [Related]
30. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
[No Abstract] [Full Text] [Related]
31. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
32. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
[TBL] [Abstract][Full Text] [Related]
33. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers.
Kim YW; Bae SM; Lim H; Kim YJ; Ahn WS
PLoS One; 2012; 7(9):e44960. PubMed ID: 22970327
[TBL] [Abstract][Full Text] [Related]
34. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
[TBL] [Abstract][Full Text] [Related]
35. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients.
Bastani A; Asghary A; Heidari MH; Karimi-Busheri F
Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884
[TBL] [Abstract][Full Text] [Related]
37. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract][Full Text] [Related]
38. A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.
Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R
Mol Cell Proteomics; 2019 Sep; 18(9):1836-1850. PubMed ID: 31289117
[TBL] [Abstract][Full Text] [Related]
39. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
40. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
